Navigation Links
Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Date:10/5/2010

condary AML. The safety and efficacy of Neulasta administration in de novo AML patients aged < 55 years with cytogenetics t(15;17) have not been established.

Neulasta should be discontinued following preliminary signs of ARDS.  Spleen size should be carefully monitored and caution exercised when administering in patients with sickle cell disease.  Safety and efficacy of Neulasta for mobilisation of blood progenitor cells in patients or healthy donors has not been adequately evaluated.  

Other adverse events of special importance associated with Neulasta include bone pain, allergic-type reactions including anaphylaxis (pegfilgrastim should be permanently discontinued in patients who experience a serious allergic reaction) and very rare cases of splenic rupture including fatal cases.  Neulasta should be administered approximately 24 hours after administration of cytotoxic chemotherapy.

About AranespAranesp was approved by the FDA in 2001 for the treatment of anemia associated with CRF for patients on dialysis and patients not on dialysis. The European Commission granted marketing authorization for the same indication in 2001 and subsequently updated it for CRF patients with symptomatic anemia in 2008.

In 2002, the FDA approved Aranesp for the treatment of anemia caused by concomitantly administered chemotherapy in patients with nonmyeloid malignancies. The European Commission authorized the treatment of anemia caused by concomitantly administered chemotherapy in patients with non-haematological malignancies in 2002 and extended it to include non-myeloid malignancies in patients receiving chemotherapy in 2003.

Important U.S. Product Safety InformationAranesp is indicated for the treatment of anemia due to the effect of concomitantly administered chemotherapy based on studies that have shown a reduction in the need for red blood cell transfusions in patients with metastatic, non-myeloid malignancies
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 VWR ... laboratory products, services and solutions, announces the redesign of its ... customers. When visiting the new site, guests ... with bold colors and vivid images.  Each country site now ... an A to Z product menu; and , the ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 /PRNewswire/ ... HOLD -- FN Media Group LLC, PIV757417 The ... Focus on Developing Orphan Drug Products & Treatments ... now OFF HOLD. Distribution time: 3 Aug 2015 ... agreements between biotech companies, military surgical research and ...
(Date:8/3/2015)... 2015  Charleston Laboratories, Inc., an emerging specialty ... development program with a Phase 1 study on ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  This novel ... for migraine headache pain and migraine-induced nausea and ... migraine headaches also suffer from nausea and vomiting," ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... , AUSTIN, Texas, Dec. 9 Ascension ... recent hiring of two veteran executives, L. Robert Johnston, Jr. ... Vice President of Marketing. "These individuals bring a wealth of ... future growth of Ascension," said Guy Mayer, CEO. "As members ...
... Dec. 9 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... to the Company,s Board of Directors. Dr. Sanders brings ... physician and professor of medicine. , "We are ... said Zola P. Horovitz, Ph.D., Chairman of the Board of ...
Cached Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4
(Date:8/3/2015)... ... 03, 2015 , ... Since 1978, the number of black males applying to ... released today by the AAMC (Association of American Medical Colleges). , Despite an ... decades, the number of black male applicants to medical school dropped to 1,337 in ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today announced the ... , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and ... launch of their Readmissions Analytics product was selected as one of four finalists ...
(Date:8/3/2015)... ... August 03, 2015 , ... A ... while an overwhelming number of Hispanics believe people can positively affect their diabetes, ... of participants queried said making diet changes was important. Far fewer participants mentioned ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and amputation , AUGUST 3, 2015 – Since winning a South by Southwest® ... Not Impossible – an organization whose mission is to develop technology for the ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4
... Genetic factors may be at play when it comes ... and vulnerability for depression// , according to a new ... the October issue of the journal Archives of General ... genetic analyses that showed that neuroticism is a strong ...
... Ooteman a Dutch researcher has stumbled upon some very ... of understanding// the biological and genetic characteristics of alcoholics, ... curb the irresistible urge to drink. ,The urge ... like Naltrexone and Acamprosate. The investigations done by the ...
... focus on U.S. soldiers seriously wounded or injured during ... //severity may predict the risk for posttraumatic stress disorder ... 2006 issue of The American Journal of Psychiatry, the ... study written by Thomas A. Grieger, M.D., and colleagues ...
... Manchester Been honored with a prized award for research ... suffer from chronic or acute back pain worldwide. ... Student annually at the Science, Engineering and Technology Student ... Ambury. ,She examined how special ‘Braces’ or ...
... immigration detention centers has been accused of providing inadequate ... the prison watchdog.// ,Chief Inspector of Prisons ... Wood Immigration Removal Centre in Bedfordshire following concerns raised ... Uganda. ,Although Owers praised the work of ...
... research reported that ragweed or hay fever symptoms could be ... vaccine developed at Johns Hopkins in Baltimore. ,Dr. ... and Allergy Center at the Johns Hopkins University School of ... fall ragweed seasons in Baltimore. ,The study was ...
Cached Medicine News:Health News:Link Between Neuroticism and Depression May be Genetic 2Health News:DNA vaccine for ragweed allergies 2
... Designed for High Throughput Screening (HTS), ... assays into HTS by sharing all ... of Analyst AD, fluorescence intensity, fluorescence ... Optimized for seamless integration into robotic ...
... for cell-based assays, the NOVOstar provides both ... the flexibility of an on-board reagent pipet. ... to plate or from three reagent stations ... unit has two injectors that can accurately ...
... High sensitivity and ... for eight different radiometric ... first system with true ... radiometric assays, by exploiting ...
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
Medicine Products: